In this age of globalization, one might assume that research, and in particular clinical trials, can be conducted in a consistent manner around the world for the benefit of the international community, but a recent review of clinical trials on Clinicaltrials.gov shows that this is not the case.

In this white paper, Infiuss Health discusses how the Omnibus bill provisions for clinical trials diversity and how this will impact on conducting  clinical trials outside the US.

Infiuss Health also offers recommendations for researchers and companies to ensure compliance with the new regulations